Amenamevir

CAS号

841301-32-4

分子式

C24H26N4O5S

主要靶点

HSV|DNA/RNA Synthesis

仅限科研使用

Cat No : CM04459

Print datasheet

Synonyms

DNASynthesis|DNA Synthesis|helicase-primase|Herpes simplex virus|HSV|ASP 2151|ASP2151|ASP-2151|Amenamevir|阿莫奈韦|Inhibitor|inhibit|RNA Synthesis|RNASynthesis



产品信息

CAS号 841301-32-4
分子式 C24H26N4O5S
主要靶点 HSV|DNA/RNA Synthesis
主要通路 DNA 损伤和修复|细胞周期|微生物学
分子量 482.55
纯度 99.86%, 此纯度可做参考,具体纯度与批次有关系,可咨询客服
储存条件 Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
别名 DNASynthesis|DNA Synthesis|helicase-primase|Herpes simplex virus|HSV|ASP 2151|ASP2151|ASP-2151|Amenamevir|阿莫奈韦|Inhibitor|inhibit|RNA Synthesis|RNASynthesis

靶点活性

Helicase-primase:14 ng/mL

体内活性

Amenamevir(ASP2151, 3-30 mg/kg/day)以剂量依赖性方式加速病毒滴度的减少,不论给药间隔如何,均可剂量依赖性降低HSV-1滴度和病损评分。根据相关性曲线,Amenamevir(口服)能完全抑制HSV-1的生长,并估算出以下药动学参数:血清中Cmax达到或超过10,000 ng/mL;AUC24h达到或超过60 μg·h/ml;T>100保持时间为21至24小时。感染后第5天,Amenamevir在血浆中的平均浓度随剂量增加而升高,3 mg Amenamevir/g或更高剂量显著降低了皮内HSV-1的滴度。

体外活性

Amenamevir对HSV-1和HSV-2的平均EC50分别为14 ng/mL(范围7.7-20)和30 ng/mL(范围15-58),而Acyclovir(ACV)的相应值分别为29 ng/mL(范围18-38)和71 ng/mL(范围45-95)。

溶解度

DMSO:15 mg/mL (31.08 mM)

细胞实验

The antiviral activities of Amenamevir and ACV against HSVs are tested using a plaque reduction assay. Briefly, HEF cells are seeded into multi-well plates and incubated until they form a monolayer. After the medium is removed, the cells are infected with HSV-1 or HSV-2, and the plates are further incubated for 1 h at 37°C. The cells are washed twice with maintenance medium and then treated with the test compound (including Amenamevir) until clear plaques appear. The cells are then fixed with 10% formalin in phosphate-buffered saline, stained with a 0.02% crystal violet solution, and the number of plaques is determined under a light microscope. The EC50, which represents the concentration of test compound needed to reduce the plaque number by 50%, is calculated using nonlinear regression analysis with a sigmoid-maximum effect (Emax) model[1].

动物实验

Female hairless mice (HOS: HR-1, 7 to 8 weeks old) are infected with a suspension of HSV-1 strain WT51 (15 μL/mouse; titer, 2×108 PFU/mL) or CI-116 (15 μL/mouse; titer, 4×107 PFU/mL) in the dorsolateral skin stripped as a small square using a needle, under anesthesia. The day of HSV-1 infection is designated day zero postinfection. Total daily doses of 1, 3, 10, 30, or 100 mg/kg/day ASP2151 are orally administered to HSV-1-infected mice (n=5) for 5 days. Amenamevir (ASP2151) treatments are started 2 to 3 h after HSV infection either as a single daily dose (every 24 h, q24h) or as two (every 12 h, q12h) or three (every 8 h, q8h) divided doses. Lesion scores and intradermal HSV-1 titers are measured on day 5 postinfection[1].

参考文献

1.Katsumata K, et al. Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection. Antimicrob Agents Chemother. 2013 Mar;57(3):1339-46.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
=
×
×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
×
=
×
C1   V1   C2   V2